

January 28, 2021

To,  
**Department of Corporate Service**  
**BSE Limited,**

Registered Office : Floor 25, P. J. Towers,  
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.  
T: 2272 1233 / 1234 | F: 2272 3121 / 3719 | www.bseindia.com

Subject : Approval of Standalone Un-Audited Financial Results for the quarter  
and nine months ended December 31, 2020.

**Reference : Centenial Surgical Suture Ltd. | Scrip Code: 531380**

Dear Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter and nine months ended December 31, 2020.
- 2). Limited Review Report for the quarter and nine months ended December 31, 2020.

You are requested to kindly take the same on your record.



Enclosures : as mentioned above.

Sincerely,  
For **CENTENIAL SURGICAL SUTURE LTD.**

  
**Vijay MAJREKAR**  
Managing Director & Chief Executive Officer  
DIN : 00804808

- ☐ **Registered Office**  
F-29, MIDC, Murbad, Thane 421401  
MAHARASHTRA  
☎ 912524222905 Fax 912524222905
- ☐ **Manufacturing Facility**  
B-17 / F-29 / F-22 MIDC, Murbad,  
Thane 421401. MAHARASHTRA  
☎ 2524223200 Fax 912524 222872
- ☐ **Sales Office - Mumbai**  
1<sup>st</sup> Floor, Palai Complex CHS Ltd.,  
Bhandarkar Road, Matunga (East),  
Mumbai 400019. MAHARASHTRA  
☎ 912224102876 Fax 912224161261
- ☐ **Sales Office - Bengaluru**  
No.12/42, Udhani Layout,  
Off. Cambridge Road, Halasur,  
Bengaluru 560008. KARNATAKA  
☎ 9180 25577791 Fax 9180 25577792
- ☐ **Sales Office - Kolkata**  
Flat No. N-1, Ground Floor, 385,  
Purbachal, Kalitola Road, P.S.Kasba  
Kolkata 700078. WEST BENGAL  
☎ 91 3324844875 Fax 91 3324844875



Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2020

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	993.28	813.66	1315.91	2409.32	4163.63	5561.43
II	Other Income	0.11	-	0.15	0.58	0.71	9.26
III	<b>Total Revenue (I + II)</b>	<b>993.39</b>	<b>813.66</b>	<b>1316.06</b>	<b>2409.90</b>	<b>4164.34</b>	<b>5570.69</b>
IV	Expenses :						
	(a) Cost of Material Consumed	374.93	375.79	562.02	1078.29	1780.76	2455.26
	(b) Purchase of Stock-in-Trade	-	-	-	-	28.80	37.02
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	(220.63)	(288.37)	(132.04)	(782.20)	(217.58)	(63.32)
	(d) Employee Benefits Expenses	282.08	238.87	277.03	745.01	768.03	1067.37
	(e) Finance Cost	65.82	44.98	26.61	135.93	85.11	218.32
	(f) Depreciation and Amortisation Expenses	35.97	43.79	19.35	118.12	51.64	155.39
	(g) Other Expenses	392.20	345.85	504.42	977.65	1478.07	1485.15
	<b>Total Expenses (IV)</b>	<b>930.37</b>	<b>760.91</b>	<b>1257.39</b>	<b>2272.79</b>	<b>3974.83</b>	<b>5355.19</b>
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	63.02	52.74	58.68	137.11	189.51	215.50
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	63.02	52.74	58.68	137.11	189.51	215.50
VIII	Tax Expense :						
	(1) Current Tax	20.80	13.71	15.67	34.51	47.70	71.58
	(2) Deferred tax	-	-	-	-	-	14.33
	<b>Total Tax Expenses</b>	<b>20.80</b>	<b>13.71</b>	<b>15.67</b>	<b>34.51</b>	<b>47.70</b>	<b>85.91</b>
IX	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	42.22	39.03	43.01	102.60	141.81	129.59
X	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period (IX+XII)	42.22	39.03	43.01	102.60	141.81	129.59
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	42.22	39.03	43.01	102.60	141.81	129.59
XVI	Details of Equity share capital						
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
XVII	Earnings Per Equity Share (for Continuing operation) :						
	(a) Basic	1.16	1.07	1.18	2.81	3.89	3.55
	(b) Diluted	1.16	1.07	1.18	2.81	3.89	3.55
XVIII	Earnings Per equity share (for Discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XIX	Earnings Per Equity Share (for Discontinued & Continuing operation) :						
	(a) Basic	1.16	1.07	1.18	2.81	3.89	3.55
	(b) Diluted	1.16	1.07	1.18	2.81	3.89	3.55

Notes:

- The Company has one reportable business segment "Medical Devices" and the above Financial Results for the Quarter and Nine Months ended December 31, 2020 in respect of CENTENIAL SURGICAL SUTURE LTD., ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 28, 2021. The above results have been subjected to limited review by the statutory auditors of the Company and the report of the statutory auditors is unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Prior period / year figures have been reclassified wherever required to conform to the classification of the current period / year, and are available on [www.bseindia.com](http://www.bseindia.com) & on [www.centenialindia.com](http://www.centenialindia.com).
- In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The company has considered internal and external information while finalising various estimates in relation to its financial results captions upto the date of approval of the financial results by the Board of Directors and the company will continue to closely monitor any material changes to future economic conditions.



for and on behalf of the Board of Directors of  
**CENTENIAL SURGICAL SUTURE LTD.**

**Vijay MAJREKAR**  
Managing Director ~ DIN : 00804808

Place : Mumbai, Maharashtra  
Date : January 28, 2021



**Mahesh Chandra & Associates**  
**Chartered Accountants**

**Independent Auditor's Review Report on the Quarter and Nine Months ended December 31, 2020 Standalone Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,  
**The Board of Directors**  
**CENTENIAL SURGICAL SUTURE LTD.**  
Registered Office : F-29, M.I.D.C., Murbad,  
Thane 421401. MAHARASHTRA.

We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of Centenial Surgical Suture Limited ("the Company") for the quarter and nine months ended December 31, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended ("the Regulation") read with SEBI Circular No: CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

This "statement" which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on January 28, 2021 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **M/s Mahesh Chandra & Associates**  
Chartered Accountants,  
Firm Registration No.: 112334W

**RAJESH BOHRA** Digitally signed by  
RAJESH BOHRA  
Date: 2021.01.28  
16:19:18 +05'30'

**RAJESH BOHRA**

Partner ~ Membership No.102587  
UDIN: 21102587AAAACH6406

Date : January 28, 2021  
Place : Mumbai, MAHARASHTRA.